HSINCHU, Taiwan and WUHAN, China, July 9, 2018 /PRNewswire/ -- JHL Biotech has announcedit received a positive Scientific Advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) related to the EU approval pathway for its proposed rituximab biosimilar, JHL1101.
The EMA, like other
JHL has also recently received a Clinical Trial Permit (CTP) from the Center for Drug Evaluation (CDE) of the SDA for a global Phase III clinical study of JHL1101 in patients with diffuse large B-cell lymphoma. Therefore, a global Phase III study of JHL1101 can be initiated in China, Europe, and other countries in the following months.
About JHL Biotech
JHL Biotech, Inc. is a biopharmaceutical company founded by a group of industry veterans with deep experience in biologics development and operations. With a mission to provide the world with affordable medicines of exceptional quality, the company is focused on research and development of new protein-based therapies and biosimilars. JHL Biotech's experienced leadership team, ongoing global clinical trials for its pipeline of biosimilar candidates and two Asia-based world-class biologics manufacturing facilities built in accordance with United States, European Union, and ICH cGMP regulations and standards uniquely position the company to be a leading global supplier of high quality biologics. JHL Biotech is backed by premier financial firms, including Kleiner Perkins Caufield & Byers, Sequoia Capital, Biomark Capital, Milestone Capital, Fidelity and the China Development Industrial Bank. For more information, please visit www.jhlbiotech.com.
Media Contact:Ellis Chu: email@example.com phone: +886 3-658-3899Jill Liu: firstname.lastname@example.org phone: +886 3-658-3899Amber Chen: email@example.com phone: +886 3-658-3899
This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," "outlook" and similar expressions. Forward-looking statements are based on management's current plans, estimates, assumptions and projections, and speak only as of the date they are made. JHL undertakes no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond the control of either company. Actual results or outcomes may differ materially from those implied by the forward-looking statements.
Subscribe to our Free Newsletters!
Wet dreams or nightfall is the involuntary ejaculation occurring during sleep. It is fairly common ...
For healthy weight loss, focus on consuming low-calorie foods such as fruits and vegetables ...
Curious about long pepper? Here we decode some amazing health benefits this wonder herb offers.View All